{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T13:31:12Z","timestamp":1750944672037},"reference-count":104,"publisher":"Elsevier","isbn-type":[{"value":"9780128139394","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/b978-0-12-813939-4.00033-4","type":"book-chapter","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:24:54Z","timestamp":1559939094000},"page":"837-846","source":"Crossref","is-referenced-by-count":3,"title":["Epigenetics in Doxorubicin Cardiotoxicity"],"prefix":"10.1016","author":[{"given":"Luciana L.","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Paulo J.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Cunha-Oliveira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0010","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","article-title":"Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study","volume":"42","author":"van Dalen","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5669","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.3.5669.503","article-title":"Clinical evaluation of adriamycin, a new antitumour antibiotic","volume":"3","author":"Bonadonna","year":"1969","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0020","first-page":"2572","article-title":"Phase I and preliminary phase II evaluation of adriamycin (NSC 123127)","volume":"30","author":"Bonadonna","year":"1970","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius","volume":"11","author":"Arcamone","year":"1969","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2017","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0045","first-page":"2467","article-title":"Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex","volume":"61","author":"Kiyomiya","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0050","first-page":"84","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2008.11.059","article-title":"Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs","volume":"378","author":"Ashley","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(02)00715-5","article-title":"Culprit and victim\u2014DNA topoisomerase II","volume":"3","author":"Kellner","year":"2002","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0070","first-page":"276","article-title":"Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines","volume":"296","author":"Bellarosa","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0075","first-page":"4543","article-title":"Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0085","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0090","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0100","series-title":"Mitochondrial Dysfunction by Drug and Environmental Toxicants. Vol II","first-page":"593","article-title":"Mitochondrial toxicity induced by chemotherapeutic drugs","author":"Ferreira","year":"2018"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00685796","article-title":"Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry","volume":"36","author":"Dobbs","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0110","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/pgs.12.205","article-title":"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity","volume":"14","author":"Jensen","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0125","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1517\/17425255.2011.610180","article-title":"Pharmacogenetics of genes across the doxorubicin pathway","volume":"7","author":"Jamieson","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0130","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0135","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1124\/dmd.108.022251","article-title":"Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver","volume":"36","author":"Kassner","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0140","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014a report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0145","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.108.024547","article-title":"Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors","volume":"37","author":"Gonzalez-Covarrubias","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0150","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0155","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1389200013338243","article-title":"Contribution of specific transport systems to anthracycline transport in tumor and normal cells","volume":"2","author":"Nagasawa","year":"2001","journal-title":"Curr Drug Metab"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0165","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190903177212","article-title":"Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood","volume":"50","author":"Rajic","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0170","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0175","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00903.x","article-title":"CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1476-4598-9-68","article-title":"DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response","volume":"9","author":"Dejeux","year":"2010","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174227","article-title":"Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1078-0432.CCR-08-0166","article-title":"DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0200","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2017-03-775569","article-title":"SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia","volume":"130","author":"Mar","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0205","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.bbadis.2017.07.030","article-title":"Berberine-induced cardioprotection and Sirt3 modulation in doxorubicin-treated H9c2 cardiomyoblasts","volume":"1863","author":"Coelho","year":"2017","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0210","doi-asserted-by":"crossref","first-page":"H962","DOI":"10.1152\/ajpheart.00832.2015","article-title":"Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice","volume":"310","author":"Pillai","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.410","article-title":"Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1\/LKB1\/AMPK pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2015.03.438","article-title":"SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells","volume":"189","author":"De Angelis","year":"2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0225","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/cvr\/cvr022","article-title":"Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53","volume":"90","author":"Zhang","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0230","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.freeradbiomed.2007.03.007","article-title":"Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury","volume":"42","author":"Daosukho","year":"2007","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"Tarasenko","year":"2012","journal-title":"Investig New Drugs"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0240","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12012-015-9327-x","article-title":"Role of DNA methylation on the expression of the anthracycline metabolizing enzyme AKR7A2 in human heart","volume":"16","author":"Hoefer","year":"2016","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","article-title":"Early biomarkers of doxorubicin-induced heart injury in a mouse model","volume":"281","author":"Desai","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0250","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00204-016-1668-0","article-title":"MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"90","author":"Chaudhari","year":"2016","journal-title":"Arch Toxicol"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0255","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0260","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12012-007-0026-0","article-title":"Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment","volume":"7","author":"Berthiaume","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tox.2017.08.011","article-title":"Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity","volume":"390","author":"Ferreira","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0270","first-page":"239","article-title":"Cardiac stem cells and progenitors: developmental biology and therapeutic challenges","volume":"117","author":"Parmacek","year":"2006","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0275","first-page":"1","article-title":"Endogenous cardiac stem cells for the treatment of heart failure","volume":"6","author":"Fuentes","year":"2013","journal-title":"Stem Cells Cloning"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0280","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12012-012-9177-8","article-title":"Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts","volume":"12","author":"Branco","year":"2012","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0285","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake","year":"2012","journal-title":"Futur Cardiol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0290","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-8703(97)70205-9","article-title":"Cardiovascular responses to dynamic submaximal exercise in children previously treated with anthracycline","volume":"133","author":"Johnson","year":"1997","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/pr.54.1.101","article-title":"Mitochondria as a pharmacological target","volume":"54","author":"Szewczyk","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0005-2728(99)00011-0","article-title":"Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration","volume":"1411","author":"Serrano","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038867","article-title":"Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific","volume":"7","author":"Pereira","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0310","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.carpath.2009.06.006","article-title":"Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy","volume":"19","author":"Lebrecht","year":"2010","journal-title":"Cardiovasc Pathol"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0315","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.bbadis.2014.09.015","article-title":"Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts","volume":"1842","author":"Moreira","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0320","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00280-009-0932-x","article-title":"Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts","volume":"64","author":"Sardao","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"42","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0325","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1207936","article-title":"Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells","volume":"23","author":"Kluza","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2014.03.001","article-title":"Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment","volume":"72","author":"Zhao","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/CS20100254","article-title":"Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats","volume":"120","author":"Ascensao","year":"2011","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0345","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0378-4274(01)00329-0","article-title":"Doxorubicin-induced persistent oxidative stress to cardiac myocytes","volume":"121","author":"Zhou","year":"2001","journal-title":"Toxicol Lett"},{"issue":"5","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0350","doi-asserted-by":"crossref","first-page":"H1466","DOI":"10.1152\/ajpheart.00795.2008","article-title":"Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro","volume":"296","author":"Mukhopadhyay","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0355","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cardfail.2004.08.161","article-title":"Superoxide dismutase activity in adriamycin-induced cardiotoxicity in humans: a potential novel tool for risk stratification","volume":"11","author":"Rohde","year":"2005","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0360","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3892\/etm.2016.3437","article-title":"Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes","volume":"12","author":"Liu","year":"2016","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0365","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","article-title":"Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function","volume":"121","author":"De Angelis","year":"2010","journal-title":"Circulation"},{"issue":"2-3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0370","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tox.2005.12.009","article-title":"Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats\u2014relevance for mitochondrial dysfunction","volume":"220","author":"Oliveira","year":"2006","journal-title":"Toxicology"},{"issue":"21","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0375","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/0006-2952(80)90050-7","article-title":"Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity","volume":"29","author":"Goormaghtigh","year":"1980","journal-title":"Biochem Pharmacol"},{"issue":"2-3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0380","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0301-4622(90)80012-V","article-title":"Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity","volume":"35","author":"Goormaghtigh","year":"1990","journal-title":"Biophys Chem"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-1119(01)00814-9","article-title":"Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage","volume":"286","author":"Paradies","year":"2002","journal-title":"Gene"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0390","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0005-2728(87)90236-2","article-title":"Effects of adriamycin on respiratory chain activities in mitochondria from rat liver, rat heart and bovine heart. Evidence for a preferential inhibition of complex III and IV","volume":"892","author":"Nicolay","year":"1987","journal-title":"Biochim Biophys Acta"},{"issue":"52","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0395","doi-asserted-by":"crossref","first-page":"52873","DOI":"10.1074\/jbc.M308366200","article-title":"Cardiolipin stabilizes respiratory chain supercomplexes","volume":"278","author":"Pfeiffer","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chemphyslip.2013.10.012","article-title":"Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes","volume":"179","author":"Mileykovskaya","year":"2014","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0405","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","article-title":"Adriamycin-induced oxidative mitochondrial cardiotoxicity","volume":"23","author":"Berthiaume","year":"2007","journal-title":"Cell Biol Toxicol"},{"issue":"7","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0415","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/S0021-9258(17)35747-2","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical","volume":"261","author":"Doroshow","year":"1986","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0420","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12012-007-0008-2","article-title":"Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis","volume":"7","author":"Wallace","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0425","first-page":"771","article-title":"Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin","volume":"61","author":"Zhou","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0430","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-015-1583-9","article-title":"p66Shc signaling is involved in stress responses elicited by anthracycline treatment of rat cardiomyoblasts","volume":"90","author":"Sampaio","year":"2016","journal-title":"Arch Toxicol"},{"issue":"18","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0435","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129303","article-title":"Gene expression profiling of H9c2 myoblast differentiation towards a cardiac-like phenotype","volume":"10","author":"Branco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-813939-4.00033-4_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2015.05.001","article-title":"Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts","volume":"334","author":"Deus","year":"2015","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0450","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/med.21280","article-title":"Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy","volume":"34","author":"Carvalho","year":"2014","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0455","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2010.3492","article-title":"The redox basis of epigenetic modifications: from mechanisms to functional consequences","volume":"15","author":"Cyr","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mito.2009.09.006","article-title":"Energetics, epigenetics, mitochondrial genetics","volume":"10","author":"Wallace","year":"2010","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cmet.2012.06.001","article-title":"Metabolic regulation of epigenetics","volume":"16","author":"Lu","year":"2012","journal-title":"Cell Metab"},{"issue":"1-2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0470","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2012.01.001","article-title":"Connecting threads: epigenetics and metabolism","volume":"148","author":"Katada","year":"2012","journal-title":"Cell"},{"issue":"7472","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0475","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature12752","article-title":"The nexus of chromatin regulation and intermediary metabolism","volume":"502","author":"Gut","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0480","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tibs.2017.11.004","article-title":"Spatiotemporal control of Acetyl-CoA metabolism in chromatin regulation","volume":"43","author":"Sivanand","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0485","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","article-title":"Influence of metabolism on epigenetics and disease","volume":"153","author":"Kaelin","year":"2013","journal-title":"Cell"},{"issue":"9","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0490","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.crvi.2005.08.007","article-title":"Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin","volume":"329","author":"Tokarska-Schlattner","year":"2006","journal-title":"C R Biol"},{"issue":"8","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0495","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4161\/cbt.7.8.6215","article-title":"A novel role for mitochondria in regulating epigenetic modification in the nucleus","volume":"7","author":"Smiraglia","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0500","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/toxsci\/kfx150","article-title":"Editor's highlight: the altered DNA methylome of chronic doxorubicin exposure in Sprague Dawley rats","volume":"159","author":"Nordgren","year":"2017","journal-title":"Toxicol Sci"},{"issue":"1-2","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0505","first-page":"65","article-title":"Effects of S-adenosylmethionine (SAMe) on doxorubicin-induced cardiotoxicity in the rat","volume":"25","author":"Russo","year":"1994","journal-title":"J Med"},{"issue":"7","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0510","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase","volume":"261","author":"Davies","year":"1986","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00109-014-1230-6","article-title":"MitoTimer: a novel protein for monitoring mitochondrial turnover in the heart","volume":"93","author":"Gottlieb","year":"2015","journal-title":"J Mol Med"},{"issue":"12","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0520","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1074\/mcp.M112.021162","article-title":"Metabolic labeling reveals proteome dynamics of mouse mitochondria","volume":"11","author":"Kim","year":"2012","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"10.1016\/B978-0-12-813939-4.00033-4_bb0525","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1474-9726.2008.00426.x","article-title":"Mitochondrial turnover in liver is fast in vivo and is accelerated by dietary restriction: application of a simple dynamic model","volume":"7","author":"Miwa","year":"2008","journal-title":"Aging Cell"}],"container-title":["Pharmacoepigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128139394000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128139394000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:09:31Z","timestamp":1721383771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128139394000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128139394"],"references-count":104,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-813939-4.00033-4","relation":{},"subject":[],"published":{"date-parts":[[2019]]}}}